ArticleJACC. CardioOncology2023
Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors.
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy.Cardio-oncology (London, England) · 2026Article
- Long-term survival rates of thalassemia patients following hematopoietic stem cell transplantation: A systematic review and meta-analysis.Hematology, transfusion and cell therapy · 2026Article
- Stratified discharge timing within mucositis cases and its association with systemic complications in hematopoietic stem cell transplant recipients: insights from a national inpatient study.Clinical oral investigations · 2026Article
- Subclinical myocardial changes after hematopoietic stem cell transplantation: limited predictive value of early biomarkers and strain imaging.Cardio-oncology (London, England) · 2026Article
- Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study.JMIR research protocols · 2026Article
- Article
- Review
- Recent Advances in Understanding the Mechanisms of Therapy-Related Cardiovascular Events in Pediatric Hematologic Malignancies.Reviews in cardiovascular medicine · 2026Review
- Platelets as immune sensors: monitoring immune dynamics and diagnosing disease states across multiple disorders.EBioMedicine · 2026Article
- Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact.JACC. CardioOncology · 2026Article
- Atrial Fibrillation After Stem Cell Transplantation: Sentinel of Systemic Vulnerability.JACC. CardioOncology · 2026Article
- Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.Frontiers in cardiovascular medicine · 2026Review
- Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis.Frontiers in cardiovascular medicine · 2026Article
- Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review.JACC. CardioOncology · 2025Review
- The utility of novel echocardiographic techniques in evaluating cardiac function in patients undergoing hematopoietic stem cell transplantation: a pilot study.Scientific reports · 2025Article
- Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation.Journal of the American Heart Association · 2025Article
- Atrial fibrillation or flutter in patients undergoing stem cell transplantation, in-hospital and post-discharge outcomes in a large nationwide sample across the United States.Cardio-oncology (London, England) · 2025Article
- CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.Journal for immunotherapy of cancer · 2025Review
- Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.Journal of cardiac failure · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 4 institutions in 1 country.
Funding
Abstract
Background: Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications. Objectives: We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients. Methods: We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT). Results: In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; Conclusions: The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.